Array trims research staff by 20%, backing off some early-stage R&D
This article was originally published in Scrip
Executive Summary
Array BioPharma is restructuring and cutting 70 positions, or about 20% of its staff, as it seeks to conserve cash. It is also looking to partner or divest two cancer compounds, one in Phase II testing and another that has completed Phase I.